Vers une stratégie multimodale: nouvelles thérapeutiques médicamenteuses de l'obésité: place, stratégie
Seance of wednesday 27 may 2026 (Chirurgie bariatrique: l'Académie reçoit la SOFFCO-MM - La chirurgie métabolique et bariatrique à l’ère des nouvelles thérapies médicamenteuses)
DOI number : 10.26299/mwy4-wz39/emem.2026.22.06
Abstract
This presentation outlines the surgical position statement on integrating anti-obesity medications (AOMs) with bariatric surgery, led by a multidisciplinary working group (FORCE, AFERO, SOFFCO-MM, SFE, SFNCM). The core message advocates a coordinated, multimodal, oncology-like approach, recognizing obesity as a chronic, relapsing disease requiring personalized care.
Systematic AOM information is recommended during preoperative preparation. AOMs may serve as a bridge to surgery, improving patient condition and potentially reducing surgical risk, but should be discontinued before the procedure. Postoperatively, AOMs become relevant when patients reach a weight plateau, experience insufficient response, or regain weight. Nutritional vigilance remains essential, including vitamin assessment and supplementation before initiating any AOM.
Regarding weight-loss targets, graded thresholds correlate with specific benefits: 5–10% loss improves metabolic markers, while 10–15%+ may alter the course of type 2 diabetes. Remission does not equal cure, and AOM responses often require long-term maintenance therapy.
Despite the rise of GLP-1 agonists, most people living with obesity still lack access to both surgery and pharmacotherapy. The conclusion reaffirms the value of a multimodal AOM + surgery strategy, with evidence-based indications and rigorous nutritional follow-up.
Systematic AOM information is recommended during preoperative preparation. AOMs may serve as a bridge to surgery, improving patient condition and potentially reducing surgical risk, but should be discontinued before the procedure. Postoperatively, AOMs become relevant when patients reach a weight plateau, experience insufficient response, or regain weight. Nutritional vigilance remains essential, including vitamin assessment and supplementation before initiating any AOM.
Regarding weight-loss targets, graded thresholds correlate with specific benefits: 5–10% loss improves metabolic markers, while 10–15%+ may alter the course of type 2 diabetes. Remission does not equal cure, and AOM responses often require long-term maintenance therapy.
Despite the rise of GLP-1 agonists, most people living with obesity still lack access to both surgery and pharmacotherapy. The conclusion reaffirms the value of a multimodal AOM + surgery strategy, with evidence-based indications and rigorous nutritional follow-up.